A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis

  • STATUS
    Recruiting
  • participants needed
    198
  • sponsor
    EA Pharma Co., Ltd.
Updated on 18 June 2021
Investigator
Public Relations Group
Primary Contact
AJM300/CT3 trial site 13 (0.0 mi away) Contact
+81 other location
mesalamine
hematochezia

Summary

The study will investigate the efficacy and safety of an oral dose of AJM300 960 milligram (mg)/dose administered three times daily for 8 weeks in participants with active ulcerative colitis.

Details
Condition Ulcerative Colitis, Ulcerative Colitis (Pediatric)
Treatment Placebo, AJM300
Clinical Study IdentifierNCT03531892
SponsorEA Pharma Co., Ltd.
Last Modified on18 June 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note